Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence
Corrado Pelaia, Cecilia Calabrese, Eugenio Garofalo, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 6, pp. 3059-3059
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Structural biology of SARS-CoV-2: open the door for novel therapies
Weizhu Yan, Yanhui Zheng, Xiao‐Tao Zeng, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 241
COVID-19 and the role of cytokines in this disease
Amin Hasanvand
Inflammopharmacology (2022) Vol. 30, Iss. 3, pp. 789-798
Open Access | Times Cited: 92
Case report: Tocilizumab for hypersensitivity reaction after oxaliplatin in a patient with NK/T-cell lymphoma
Juanyan Liao, Ming Jiang
Frontiers in Pharmacology (2025) Vol. 15
Open Access | Times Cited: 1
Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study
Renato Pascale, Zeno Pasquini, Michele Bartoletti, et al.
JAC-Antimicrobial Resistance (2021) Vol. 3, Iss. 4
Open Access | Times Cited: 68
COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges
Saikat Dewanjee, Ramesh Kandimalla, Rajkumar Singh Kalra, et al.
Cells (2021) Vol. 10, Iss. 12, pp. 3291-3291
Open Access | Times Cited: 54
Multisystem Inflammatory Syndrome and Autoimmune Diseases Following COVID-19: Molecular Mechanisms and Therapeutic Opportunities
Parastoo Hosseini, Mohammad Sadegh Fallahi, Gisou Erabi, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 39
From Infection to Immunity: Understanding the Response to SARS-CoV2 Through In-Silico Modeling
Filippo Castiglione, Debashrito Deb, Anurag P. Srivastava, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 46
Ocular neuroinflammatory response secondary to SARS-CoV-2 infection-a review
Yun Zhao, Ying Tang, Qi Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Preclinical Retinal Disease Models: Applications in Drug Development and Translational Research
Sudha Priya Soundara Pandi, Hanagh R. Winter, Madeleine Smith, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 293-293
Open Access
Targeting the PI3K/Akt/mTOR pathway: A therapeutic strategy in COVID-19 patients
Rasha Abu Eid, Frank J. Ward
Immunology Letters (2021) Vol. 240, pp. 1-8
Open Access | Times Cited: 35
Drugs for COVID-19: An Update
Jessica Ceramella, Domenico Iacopetta, Maria Stefania Sinicropi, et al.
Molecules (2022) Vol. 27, Iss. 23, pp. 8562-8562
Open Access | Times Cited: 23
Cellular metabolic basis of altered immunity in the lungs of patients with COVID-19
Shuangyan Li, Fuxiaonan Zhao, Jing Ye, et al.
Medical Microbiology and Immunology (2022) Vol. 211, Iss. 1, pp. 49-69
Open Access | Times Cited: 18
Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules
Chunye Zhang, Ming Yang
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 11, pp. 6083-6083
Open Access | Times Cited: 15
Establishment of sex-specific predictive models for critical illness in Chinese people with the Omicron variant
Rui Yang, Xin Guan, Ziguang Niu, et al.
Frontiers in Microbiology (2024) Vol. 14
Open Access | Times Cited: 2
Unravelling Insights into the Evolution and Management of SARS-CoV-2
Aganze Gloire-Aimé Mushebenge, Samuel Chima Ugbaja, Nonkululeko Avril Mbatha, et al.
BioMedInformatics (2024) Vol. 4, Iss. 1, pp. 385-409
Open Access | Times Cited: 2
Specific cytokines of interleukin-6 family interact with S100 proteins
Alexey S. Kazakov, Andrey S. Sokolov, Maria E. Permyakova, et al.
Cell Calcium (2021) Vol. 101, pp. 102520-102520
Closed Access | Times Cited: 19
Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology
George J. Kontoghiorghes
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6735-6735
Open Access | Times Cited: 13
Age-related Differences in Immune Reactions to SARS-CoV-2 Spike and Nucleocapsid Antigens
Patrick Morhart, Sven Kehl, Wolfgang Schuh, et al.
In Vivo (2023) Vol. 37, Iss. 1, pp. 70-78
Open Access | Times Cited: 6
The need for a multi-level drug targeting strategy to curb the COVID-19 pandemic
George J. Kontoghiorghes, Stella Fetta, Christina Kontoghiorghe
Frontiers in Bioscience-Landmark (2021) Vol. 26, Iss. 12
Open Access | Times Cited: 14
Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm
Abdullahi Rabiu Abubakar, Rahnuma Ahmad, Adekunle Babajide Rowaiye, et al.
Life (2022) Vol. 12, Iss. 4, pp. 478-478
Open Access | Times Cited: 10
Anti-inflammatory effects of medications used for viral infection-induced respiratory diseases
Mutsuo Yamaya, Akiko Kikuchi, Mitsuru Sugawara, et al.
Respiratory Investigation (2022) Vol. 61, Iss. 2, pp. 270-283
Open Access | Times Cited: 9
Frontiers and hotspots evolution in cytokine storm: A bibliometric analysis from 2004 to 2022
Junyi Shen, Jiaming Li, Yuqi Lei, et al.
Heliyon (2024) Vol. 10, Iss. 10, pp. e30955-e30955
Open Access | Times Cited: 1
COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging association, therapeutic options, and challenges
Ramesh Kandimalla, Saikat Dewanjee, Rajkumar Singh Kalra, et al.
(2021)
Open Access | Times Cited: 12
Tocilizumab-Induced Unexpected Increase of Several Inflammatory Cytokines in Critically Ill COVID-19 Patients: The Anti-Inflammatory Side of IL-6
Fanny Ponthieux, Nicolás Dauby, Evelyne Maillart, et al.
Viral Immunology (2022) Vol. 35, Iss. 1, pp. 60-70
Open Access | Times Cited: 8
Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome
Oleksandr Oliynyk, Wojciech Barg, Anna Ślifirczyk, et al.
Viruses (2021) Vol. 13, Iss. 6, pp. 1067-1067
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top